Landmark editorial identifies microbes as major cause of Alzheimer's disease

March 9, 2016 by Joe Paxton
Diagram of the brain of a person with Alzheimer's Disease. Credit: Wikipedia/public domain.

A worldwide team of senior scientists and clinicians have come together to produce an editorial which indicates that certain microbes - a specific virus and two specific types of bacteria—are major causes of Alzheimer's disease. Their paper, which has been published online in the highly regarded peer-reviewed journal, Journal of Alzheimer's disease, stresses the urgent need for further research—and more importantly, for clinical trials of anti-microbial and related agents to treat the disease.

This major call for action is based on substantial published evidence and research into Alzheimer's. The team's landmark editorial summarises the abundant data implicating these microbes, but until now this work has been largely ignored or dismissed as controversial—despite the absence of evidence to the contrary. Therefore, proposals for the funding of have been refused, despite the fact that over 400 unsuccessful clinical trials for Alzheimer's based on other concepts were carried out over a recent 10-year period.

Opposition to the microbial concepts resembles the fierce resistance to studies some years ago which showed that viruses cause certain types of cancer, and that a bacterium causes stomach ulcers. Those concepts were ultimately proved valid, leading to successful clinical trials and the subsequent development of appropriate treatments.

Professor Douglas Kell of The University of Manchester's School of Chemistry and Manchester Institute of Biotechnology is one of the editorial's authors. He says that supposedly sterile red blood cells were seen to contain dormant microbes, which also has implications for blood transfusions. "We are saying there is incontrovertible evidence that Alzheimer's disease has a dormant microbial component, and that this can be woken up by iron dysregulation. Removing this iron will slow down or prevent cognitive degeneration – we can't keep ignoring all of the evidence."

Professor Resia Pretorius of the University of Pretoria, who worked with Douglas Kell on the editorial, said "The microbial presence in blood may also play a fundamental role as causative agent of systemic inflammation, which is a characteristic of Alzheimer's disease—particularly, the component and endotoxin, lipopolysaccharide. Furthermore, there is ample evidence that this can cause neuroinflammation and amyloid-β plaque formation."

The findings of this editorial could also have implications for the future treatment of Parkinson's disease, and other progressive neurological conditions.

Explore further: Antidepressant use begins years before Alzheimer's diagnosis

Related Stories

Antidepressant use begins years before Alzheimer's diagnosis

March 4, 2016
Antidepressants are frequently prescribed to persons with Alzheimer's disease before the diagnosis, according to a recent study from the University of Eastern Finland. Among persons with Alzheimer's disease, the initiation ...

Blocking inflammation prevents cell death, improves memory in Alzheimer's disease

February 29, 2016
Using a drug compound created to treat cancer, University of California, Irvine neurobiologists have disarmed the brain's response to the distinctive beta-amyloid plaques that are the hallmark of Alzheimer's disease.

Evidence of a lipid link in the inherited form of Alzheimer's disease

February 9, 2016
Australian researchers have found biochemical changes occurring in the blood, in the rare inherited form of Alzheimer's disease. Changes in these fat-like substances, may suggest a method to diagnose all forms of Alzheimer's ...

Researchers work to block harmful behavior of key Alzheimer's enzyme

February 25, 2016
Enzymes rarely have one job. So, attempts to shut down the enzyme that causes the hallmarks of Alzheimer's disease often mean side effects, because these therapies prevent the enzyme from carrying out many other functions. ...

Dementia plaques attack language center of brain

March 7, 2016
The recent ability to peer into the brain of living individuals with a rare type of language dementia, primary progressive aphasia (PPA), provides important new insights into the beginning stages of this disease—which results ...

Could blood pressure drugs have a role in Alzheimer's disease treatment?

January 29, 2016
In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer's disease, say researchers at Georgetown University Medical Center (GUMC) and the National ...

Recommended for you

Researchers reveal new details on aged brain, Alzheimer's and dementia

November 21, 2017
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that ...

Dementia study sheds light on how damage spreads through brain

November 20, 2017
Insights into how a key chemical disrupts brain cells in a common type of dementia have been revealed by scientists.

Researchers describe new biology of Alzheimer's disease

November 20, 2017
In a new study, researchers from Boston University School of Medicine (BUSM) describe a unique model for the biology of Alzheimer's disease (AD) which may lead to an entirely novel approach for treating the disease. The findings ...

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

Biomarker may predict early Alzheimer's disease

November 10, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer's disease (AD). The discovery, published in Nature Communications, may ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.